Replies to post #61482 on Biotech Values

[upndown1313]

You probably need to put MK-7009 in the top 3.

[Preciouslife1]

Hepatitis C: Identification Of A Protein That Inhibits The Virus

http://www.sciencedaily.com/releases/2008/04/080414213816.htm

(Apr. 17, 2008) — Scientists in the Laboratoire Hépatite C of the Institut de Biologie de Lille in collaboration with INSERM Unit 602 and a laboratory at Stanford University have provided evidence of a protein, called EWI-2wint, that inhibits the hepatitis C virus at an early stage of its infective cycle. This research suggests possible new perspectives for the development of therapies to block the virus before it enters a cell.

Hepatitis C is a major public health problem that affects some 130 million people throughout the world. In France, where there are about 5000 new cases each year, it is estimated that half a million people could be affected by this disease. The causal agent is the hepatitis C virus (HCV) which targets cells in the liver called hepatocytes.
HCV infection is usually chronic (60% to 80% of cases) and in the long term can lead to the development of cirrhosis and liver cancer.

Unlike the hepatitis A and B viruses, there is no vaccine to combat this virus. Furthermore, the treatments employed are only of limited efficacy (the failure rate reaches around 40%), and they involve considerable side effects. It is therefore crucial to develop new antiviral compounds to control this infection.

HCV uses at least three receptors to enter and infect a hepatocyte. One of these receptors is the CD81 protein, which has the particular characteristic of associating with numerous other proteins. It was by studying these CD81 partner proteins that the researchers identified the EWI-2wint protein, which prevents the recognition of CD81 by the hepatitis C virus and inhibits it at a very early stage in its infective cycle. This protein is present in other types of cells, which could explain why they are not infected by HCV. Discovery of the role of EWI-2wint in hepatocytes has demonstrated the complexity of the mechanisms of entry of HCV into its target cells, and opens the way to new therapeutic approaches.

Journal reference: The CD81 partner EWI-2wint inhibits hepatitis C virus entry. Vera Rocha-Perugini, Claire Montpellier, David Delgrange, Czeslaw Wychowski, François Helle, André Pillez, Hervé Drobecq, François Le Naour, Stéphanie Charrin, Shoshana Levy, Eric Rubinstein, Jean Dubuisson, Laurence Cocquerel. PLoS One. April 2, 2008.

This research was supported by the ANRS.
Adapted from materials provided by CNRS.

[DewDiligence]

HCV: Most Likely to Succeed (IMHO)

[Updated links for Telaprevir, Boceprevir,
Locteron, TMC435350, R7128, R1626,
Ifn-alpha-XL, and IDX184 for the data
presentations at EASL.]


The following paragraphs are in descending order of likelihood of success. (Paragraphs 6 and 8 are “catchall” groupings that do not explicitly mention all of the applicable drug candidates within the grouping.)

1. Telaprevir (VRTX/JNJ; phase-3): #msg-26228377, #msg-28746843, #msg-28749322.

2. ITMN-191/R7227 (ITMN/Roche; phase 1b): #msg-28091523; and Boceprevir (SGP; phase-2): #msg-28820981.

3. Locteron (OctoPlus/Biolex; phase-2), a long-acting interferon made in transgenic plants: #msg-28786162.

4. Various oral agents in phase-1 or phase-2 trials that use an established MoA. These include TMC435350 (Medivir/JNJ; entering phase-2): #msg-28785830; R7128 (VRUS/Roche; phase-1b): #msg-28837612; and R1626 (Roche; phase-2): #msg-28821034.

5. The “other” interferons: Albuferon (HGSI/NVS; dose reduced in phase-3): #msg-26199740; IFN-alpha-XL (FLML; phase-1): #msg-28837983; and IFN-Lambda (ZGEN; phase-1): #msg-16610804. I’m excluding MAXY’s Maxy-alpha, which has been on life support since Roche dropped the program: #msg-24801678.

6. Miscellaneous very-early-stage compounds that use an established MoA; e.g. IDX184 from IDIX: #msg-28715477, #msg-26915921.

7. GS9190 (GILD; phase-1), which has caused QT-prolongation: #msg-24268443.

8. Miscellaneous early-stage compounds that use novel MoA’s; e.g. Sirna-034, now owned by MRK: #msg-12665661.

JMHO, FWIW